Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
OpenAI in talks with Samsung to power AI features, report says
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
S. Korea not to attend Sado mine memorial: foreign ministry
-
8
South Korean military plans to launch new division for future warfare
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
Kang Stem Biotech’s stem cell atopic injection approved for further clinical trials
By 황유미Published : July 14, 2016 - 16:03
[DISCLOSURE] Kang Stem Biotech (217730) announced on July 14 that Furestem-AD Injection has got approval from the Ministry of Food and Drug Safety to initiate phase 2b of its clinical trial.
Furestem-AD Injection is a cord blood-derived stem cell treatment for moderately subacute and chronic atopic dermatitis, the first of its kind to be developed in the world.
Furestem-AD Injection is a cord blood-derived stem cell treatment for moderately subacute and chronic atopic dermatitis, the first of its kind to be developed in the world.
